After purchasing this CME Certification, you will receive a PDF download in your email containing the article and the evaluation. If you do not receive it, please check your spam box or contact kristy@acro.org.

The article, “Making Sense of the 2026 Centers for Medicare and Medicaid Services (CMS) Radiation Oncology Treatment Delivery Codes: Historical Context and Practical Applications for Clinicians” has been approved for 1 AMA PRA Category 1 credit.  ^TM 

Target Audience:
Physicians (M.D. and D.O.) needing credit for relicensure or initial licensure.

Learning Objectives:

• Recognize that coding for radiotherapy services has changed, effective 2026.
• Understand appropriate utilization of radiation codes and levels of service.
• Recognize what does and what does not constitute qualifying criteria for each level.

Date Credit Expires: 3/19/2028

Faculty Disclosure Information:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Miami-Dade County Medical Association and the American College of Radiation Oncology. The Miami-Dade County Medical Association is accredited by the Florida Medical Association to provide continuing medical education for physicians.

The Miami-Dade County Medical Association designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

None of the planners or faculty of this activity had any financial relationships to disclose except for Paul Wallner who was an employee for Genesiscare USA (relationship has ended), a consultant for Health Management Associates, and an advisory board member for Nanocan Therapeutices, Inc. and Christopher Jahraus who is a consultant for RADformation, has other financial/material support from Klarity (Expert Witness) (relationship has ended), is a stock owner/investor in the privately held company Fuse Oncology, and was an advisory board member with Elekta (relationship has ended). All of the financial relationships identified for these planners and faculty have been mitigated.

Questions:
If you have any questions, please contact Kristy Williford.